20+ years of transformation, digital/IT and transaction experience
Expertise in complex supply chain management and operational issues
Focuses on the consumer-packaged goods, pharma and medical device industries
London
Twitter
LinkedIn
Copied!
Jan Diederichsen is a Senior Director with Alvarez & Marsal Corporate Performance Improvement in London. He brings more than 20 years of transformation, digital/IT and transaction experience in the consumer-packaged goods, pharma and medical device industries.
Mr. Diederichsen specializes in helping global corporations and private equity firms deliver transactions, turnaround programs and transformations covering complex supply chain management (SCM) and operational issues, technology and digital thought leadership, technology aspects of M&A, and operational and commercial due diligence.
Prior to joining A&M, Mr. Diederichsen conducted the buy-side operational and IT due diligence for the acquisition of several contract development and manufacturing organization (CDMO) sites in Europe and the U.S. He conducted in-person visits to evaluate operational, manufacturing and quality aspects, assessed IT applications and infrastructure, and executed an ALCOA+ based data integrity assessment to identify current maturity and needs for the post-acquisition phase.
Previously, Mr. Diederichsen led the SCM and digital transformation for one of the largest Eastern European pharma companies. He did a diagnostic of their value chain that addressed major cost reduction and transformation objectives related to inventory reduction, missed sales reduction and cost-to-serve optimization by reducing inventory by 10 percent, establishing S&OP governance, and redesigning the supply chain, improving cost-to-serve by 15 percent.
Mr. Diederichsen earned a bachelor’s degree in business and an MBA (operations and SCM focus) from the University of Wales.
Wie die richtige ERP-Implementierung im Pharmasektor nicht nur über den Erfolg eines Unternehmens entscheidet, sondern auch von Patienten wahrgenommen wird
Our whitepaper delves into the essential strategies for overcoming these hurdles and addressing challenges from data inconsistencies to compliance risks. It emphasizes the importance of realistic planning, use of the right system integrators, regular compliance audits, and strategic resource allocation to mitigate these risks.
A&M’s EMEA Healthcare & Life Sciences and Ops & Supply Chain teams have shared their predictions for CDMOs in 2030, and their perspectives on what CDMOs should be addressing now to achieve success in the future.
As global challenges continue, asset-light pharmaceutical companies will remain under increased pressure for the rest of 2022 and beyond. How can asset-light companies create value in a disrupted market? A&M shares 5-value levers for asset-light pharmaceutical businesses.
Latest insightsThe latest insights from Jan Diederichsen's team
We are pleased to share the inaugural Alvarez & Marsal Distress Alert Southeast Asia report, a significant milestone in our effort to generate insights into the region’s distress market.
